Krystal Biotech, Inc.
KRYS
$341.66
+5.66%
Krystal Biotech is a commercial-stage biotechnology company focused on developing and commercializing genetic medicines for diseases with high unmet medical needs, operating within the healthcare sector. The company is a distinct player as an integrated platform company, leveraging its patented HSV-1-based gene therapy technology to create and manufacture its own therapies, most notably VYJUVEK. The current investor narrative is driven by the successful commercial launch and international expansion of VYJUVEK, which has rapidly transitioned the company to profitability, fueling a debate about the sustainability of its growth trajectory and the potential of its broader pipeline to expand beyond its initial rare disease focus.…
KRYS
Krystal Biotech, Inc.
$341.66
Related headlines
KRYS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Krystal Biotech, Inc.'s 12-month outlook, with a consensus price target around $444.16 and implied upside of +30.0% versus the current price.
Average Target
$444.16
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$273 - $444
Analyst target range
Analyst coverage appears limited with only 3 analysts providing estimates, but institutional ratings data shows consistent and recent bullish sentiment from major firms including Citigroup, Goldman Sachs, and Jefferies, all maintaining Buy ratings following the Q4 2025 earnings report in February 2026. The average revenue estimate for the forward period is $1.73 billion, with a range from $1.64 billion to $1.82 billion, indicating high conviction in continued strong commercial execution but also some variability in growth expectations. The relatively wide target range implied by the revenue estimates signals ongoing uncertainty typical for commercial-stage biotechs regarding the exact trajectory of market penetration and future pipeline readouts, though the unanimous bullish ratings from active covering firms provide a strong signal of institutional confidence in the near-to-medium term outlook.
KRYS Technical Analysis
The stock is in a sustained, powerful uptrend, evidenced by a 126.59% gain over the past year. With a current price of $317.97, it is trading near the top of its 52-week range, approximately 93% of the way from its low of $127.99 to its high of $331.49, indicating strong momentum but also positioning it at levels vulnerable to a pullback or consolidation. Recent momentum remains robust but shows signs of deceleration from the explosive longer-term trend; the stock is up 28.60% over the past three months but only 1.72% over the past month, suggesting a potential pause or consolidation phase after the significant run-up. The stock's beta of 0.528 indicates it has been significantly less volatile than the broader market, which is unusual for a biotech but may reflect its transition to a commercial, profitable entity. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $331.49 and support at the 52-week low of $127.99, though more relevant near-term support likely resides around the $290-$300 area where the price has recently consolidated; a decisive breakout above $331.49 would signal a continuation of the primary bull trend, while a breakdown below the $290 support could indicate a deeper correction is underway.
Beta
0.53
0.53x market volatility
Max Drawdown
-15.9%
Largest decline past year
52-Week Range
$128-$348
Price range past year
Annual Return
+162.8%
Cumulative gain past year
| Period | KRYS Return | S&P 500 |
|---|---|---|
| 1m | +17.1% | +0.3% |
| 3m | +32.4% | +12.3% |
| 6m | +41.9% | +8.9% |
| 1y | +162.8% | +24.0% |
| ytd | +38.4% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KRYS Fundamental Analysis
Revenue growth is strong and accelerating, with Q4 2025 revenue of $107.1 million representing a 17.5% year-over-year increase, building on a multi-quarter trend of sequential growth from $88.2 million in Q1 2025. The company is solidly profitable with a net income of $51.4 million in the latest quarter, and it boasts exceptional gross margins of 89.8%, which have remained consistently high above 92% in prior quarters, indicating a highly scalable product with strong pricing power. The balance sheet is exceptionally healthy, featuring a massive cash position of $496.3 million, negligible debt with a debt-to-equity ratio of 0.0077, and robust free cash flow generation of $188.9 million on a trailing twelve-month basis, providing ample internal funding for further growth and pipeline development without reliance on dilutive financing.
Quarterly Revenue
$107105000.0B
2025-12
Revenue YoY Growth
+0.17%
YoY Comparison
Gross Margin
+0.89%
Latest Quarter
Free Cash Flow
$188914000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KRYS Overvalued?
Given the company's positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE is 34.84x, while the forward PE is 31.54x; the modest discount of the forward multiple suggests the market expects earnings growth but is not pricing in an extreme acceleration. Compared to typical biotechnology industry averages, a PE in the low-to-mid 30s is at a premium, which appears justified by Krystal's unique profile as a profitable, commercial-stage gene therapy company with a validated platform, superior margins exceeding 90%, and a clean balance sheet, unlike many pre-revenue or cash-burning biotech peers. Historically, the stock's current trailing PE of 34.84x sits above its own historical range observed over the past two years, which has seen significant volatility from deeply negative values during pre-profitability to a recent peak; trading near its own historical highs suggests the market has fully priced in the success of VYJUVEK's launch, leaving little room for error and requiring execution on pipeline catalysts to justify further multiple expansion.
PE
34.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -26x~1336x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.9x
Enterprise Value Multiple